CytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of “Hold” from Brokerages
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned an average recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $28.50.
Several equities analysts recently issued reports on CTMX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a report on Wednesday, April 26th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 29th. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright assumed coverage on CytomX Therapeutics in a report on Monday, March 27th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Instinet boosted their price target on CytomX Therapeutics from $21.00 to $32.00 and gave the stock a “sell” rating in a report on Monday, March 20th.
CytomX Therapeutics (CTMX) traded up 1.71% on Tuesday, reaching $16.68. The company had a trading volume of 148,435 shares. The company’s 50-day moving average is $14.35 and its 200-day moving average is $13.85. The company’s market capitalization is $612.97 million. CytomX Therapeutics has a 52-week low of $9.81 and a 52-week high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.32. The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $2.10 million. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. Equities analysts anticipate that CytomX Therapeutics will post ($1.36) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “CytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of “Hold” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/11/cytomx-therapeutics-inc-ctmx-receives-consensus-rating-of-hold-from-brokerages.html.
In related news, major shareholder Kevin P. Starr sold 28,357 shares of the stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $16.36, for a total value of $463,920.52. Following the completion of the transaction, the insider now directly owns 31,419 shares of the company’s stock, valued at approximately $514,014.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $15.47, for a total value of $38,675.00. Following the completion of the transaction, the chief financial officer now directly owns 22,126 shares of the company’s stock, valued at $342,289.22. The disclosure for this sale can be found here. Insiders have sold 65,200 shares of company stock worth $1,036,623 in the last 90 days. 8.00% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the company. TFS Capital LLC acquired a new position in shares of CytomX Therapeutics during the first quarter worth about $247,000. Swiss National Bank raised its position in shares of CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after buying an additional 4,300 shares during the period. Regents of The University of California raised its position in shares of CytomX Therapeutics by 48.1% in the first quarter. Regents of The University of California now owns 70,584 shares of the biotechnology company’s stock worth $1,219,000 after buying an additional 22,918 shares during the period. Wells Fargo & Company MN raised its position in shares of CytomX Therapeutics by 52.8% in the first quarter. Wells Fargo & Company MN now owns 22,424 shares of the biotechnology company’s stock worth $387,000 after buying an additional 7,747 shares during the period. Finally, Strs Ohio acquired a new position in shares of CytomX Therapeutics during the first quarter worth about $207,000. 52.28% of the stock is owned by institutional investors and hedge funds.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.